Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Sees Large Growth in Short Interest

Key Points

• Short interest surged 979.7% to 1,348,635 shares as of October 15, up from 124,913 shares at the end of September. About 0.1% of Coloplast’s shares are sold short, representing 1.6 days of average trading volume.
• Coloplast shares fell 1.2% to $7.24, while remaining above their 50-day and 200-day moving averages. The stock’s 52-week range is $5.64 to $9.70, with a market capitalization of approximately $16.32 billion.
• The company’s latest quarterly results met expectations with EPS of $0.10 and exceeded revenue estimates, reporting $1.14 billion versus the $1.11 billion consensus forecast. Analysts expect approximately $0.40 in EPS for the current fiscal year.

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 1,348,635 shares, an increase of 979.7% from the September 30th total of 124,913 shares. Based on an average daily volume of 837,048 shares, the short-interest ratio is presently 1.6 days. Approximately 0.1% of the company's shares are sold short.

Coloplast A/S Trading Down 1.2%

OTCMKTS CLPBY traded down $0.09 during trading hours on Monday, hitting $7.24. 65,939 shares of the company's stock were exchanged, compared to its average volume of 436,922. The stock has a 50-day simple moving average of $6.78 and a 200 day simple moving average of $6.47. Coloplast A/S has a 1-year low of $5.64 and a 1-year high of $9.70. The firm has a market cap of $16.32 billion, a price-to-earnings ratio of 38.11, a PEG ratio of 2.61 and a beta of 0.21. The company has a current ratio of 1.56, a quick ratio of 0.94 and a debt-to-equity ratio of 1.51.

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 18th. The company reported $0.10 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.10. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a return on equity of 39.27% and a net margin of 9.68%. On average, equities analysts forecast that Coloplast A/S will post 0.40 EPS for the current fiscal year.

About Coloplast A/S

Coloplast A/S is a Denmark-based medical technology company that develops, manufactures and markets products designed to help people manage intimate health conditions. Its core businesses include ostomy care, continence care, wound and skin care, and interventional urology. The company's products are used by patients and healthcare professionals in hospitals, clinics and home-care settings.

Coloplast was founded in Denmark in 1957 after nurse Elise Sørensen helped develop an adhesive ostomy bag for her sister, who had undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.